DURECT (NASDAQ:DRRX) Announces Quarterly Earnings Results

DURECT (NASDAQ:DRRX) released its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.12), Zacks reports. The company had revenue of $2.30 million during the quarter, compared to the consensus estimate of $6.91 million. DURECT had a negative net margin of 198.58% and a negative return on equity of 300.62%.

DURECT Price Performance

Shares of NASDAQ:DRRX remained flat at $0.81 during midday trading on Thursday. The stock had a trading volume of 59,654 shares, compared to its average volume of 53,861. DURECT has a 12 month low of $0.70 and a 12 month high of $1.88. The stock has a fifty day moving average of $0.80 and a 200 day moving average of $1.01. The firm has a market capitalization of $25.02 million, a price-to-earnings ratio of -1.32 and a beta of 0.91.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DRRX. StockNews.com assumed coverage on shares of DURECT in a research report on Thursday. They set a “sell” rating for the company. HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a research note on Thursday.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.